Shares of Novo Nordisk plunged after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer's disease failed to meet its main goal.

Shares of Novo Nordisk plunged after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer's disease failed to meet its main goal.

Outcome is blow to one of Europe’s largest listed companies

La acción llega a caer un 12% hasta sus precios mínimos en más de cuatro años

The company said the weight loss and diabetes treatment drug failed to show any significant reduction in the progression of Alzheimer's disease in patients.

Report dashes hopes for new use for blockbuster weight-loss drug

There were initial hopes that the drug in weight loss jab Wegovy could slow progression of dementia.

The stock of the Wegovy and Ozempic maker is down nearly 50% year to date.